Mission

BioZone Laboratories is a global developer, manufacturer, and marketer of unique products and technologies that enhance the performance and delivery of active ingredients and improve personal health. BioZone is committed to exceeding its customers' expectations through excellence and continuous innovation. We are responsible to our customers, our investors, and the countries in which we operate worldwide, and are committed to acting as a responsible, valued contributor to international health.

Company Summary

Since 1989, BioZone Laboratories, Inc. has operated as a developer, manufacturer, and marketer of over-the-counter drugs and preparations, cosmetics, and nutritional supplements. BioZone has developed hundreds of products throughout its history and sold millions of units. The Company's strong customer base is made up of large, well-known industry leaders.

Company History

BioZone was founded by Daniel Fisher, President, and Dr. Brian Keller, Executive Vice President. The founders steered the Company in the direction of developing scientific technology for drug delivery systems. In its early years as a contract manufacturer, the Company focused on building its customer base in the cosmetics and dermatology market, gaining credibility and a reputation for quality and reliability in both the scientific community and marketplace as a whole.

In the mid-1990s, BioZone initiated an aggressive research and development program in conjunction with the late Dr. Dan Lasic, then the world's leading authority on liposomes, and its own in-house scientific team led by Dr. Brian Keller. Medical science had long recognized the potential of liposome molecules as a vehicle to deliver encapsulated drugs. BioZone, over a five-year period, discovered a self-forming lipid later trademarked QuSomes. These were much more efficient and less costly to synthesize than traditional liposomes, and also more effective in passively targeting encapsulated drugs to the specific target sites. BioZone also discovered how to successfully apply the technology of oral delivery in an encapsulation technology trademarked HyperSorb and via transdermal delivery with iontophoresis.

The Company also focused its attention on proprietary drug formulations and achieved its objective of developing an analgesic anti-inflammatory compound. In the late '90s the Company discovered a group of molecules capable of blocking the enzyme PLA2 that leads to an inflammatory response and pain via the synthesis of prostaglandin. It named this product Inflacin. Biozone licenses Inflacin for new drugs.

Contract Manufacturing

BioZone's core business, as a branded and private label contract manufacturer, can be separated into two areas, by the type of formulation and method of application:

• Topical compositions, which resemble traditional creams, lotions, and ointments in appearance and use.
• Liquid compositions that can be absorbed sublingually, nasal spray products, or liquid ingestion products.

Virtually all of BioZone's product line utilizes some aspect of its proprietary technology, resulting in competitive advantages and supporting higher profit margins. BioZone typically wins business on quality and effectiveness of product, excellent customer relations, and prompt fulfillment. The Company is also quick to respond to customer needs.

Technology Licensing

The Company's dedication to Research and Development has resulted in its ability to develop and market unique products known for their efficacy. BioZone is embarking on the path to commercialize its considerable intellectual property in the prescription area, focusing on several drug delivery systems and a prescription version of Inflacin.